Company news

Pulse Biosciences, Inc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Pulse Biosciences to Present at Stifel 2026 Healthcare Conference

October 29, 2026

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

October 22, 2026

Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center

October 14, 2026

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 9, 2026

Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026

October 8, 2026

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

October 7, 2026

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

September 15, 2026

Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results

August 6, 2026

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

July 30, 2026

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

July 29, 2026

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

July 21, 2026

Pulse Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)

July 16, 2026

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 27, 2026

ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million

May 12, 2026

Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference

May 8, 2026

Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase

May 6, 2026

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

May 4, 2026

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

April 25, 2026

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

April 20, 2026

Pulse Biosciences to Host Analyst Event on April 25, 2026

April 17, 2026

Pulse Biosciences Strengthens Executive Leadership Team

April 8, 2026

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

April 6, 2026

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

April 2, 2026

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

March 16, 2026

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

March 11, 2026

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

March 8, 2026

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

March 4, 2026

Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

March 3, 2026

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

February 20, 2026

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

February 19, 2026

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

February 4, 2026

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

February 3, 2026

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

February 2, 2026

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

January 8, 2026

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

January 6, 2026

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 28, 2025

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 18, 2025

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

December 17, 2025

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

December 8, 2025

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

November 5, 2025

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

November 4, 2025

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

October 23, 2025

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

October 21, 2025

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 9, 2025

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 6, 2025

Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting

September 9, 2025

Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation

September 7, 2025

Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study

September 1, 2025

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

August 25, 2025

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

August 11, 2025

Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.